Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...